{"id":789475,"date":"2026-07-28T14:50:09","date_gmt":"2026-07-28T14:50:09","guid":{"rendered":"https:\/\/www.newsbeep.com\/us\/789475\/"},"modified":"2026-07-28T14:50:09","modified_gmt":"2026-07-28T14:50:09","slug":"icon-to-deploy-claude-ai-across-clinical-trial-lifecycle","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/us\/789475\/","title":{"rendered":"ICON to Deploy Claude AI Across Clinical Trial Lifecycle"},"content":{"rendered":"

Editor\u2019s Take: From drug formulation<\/a> to workflow automation<\/a>, artificial intelligence (AI) is transforming life sciences. ICON is the latest company to expand its adoption of AI.<\/p>\n

ICON plc<\/a> has entered a multi-year collaboration with Anthropic to bring Claude\u2019s AI capabilities across the clinical trial lifecycle\u2014further advancing ICON\u2019s digital innovation and AI strategy<\/a>, and building on Orbis, ICON\u2019s secure, governed, agentic AI platform.<\/p>\n

Through this collaboration, ICON will work closely with Anthropic\u2019s Life Sciences research team to explore and apply technologies with the goal of accelerating innovation across clinical development.<\/p>\n

Barry Balfe, CEO of ICON plc, said, \u201cWe are determined to lead AI acceleration of clinical trials. Working with Anthropic gives us direct access to frontier AI capability and the people who build it. By combining ICON\u2019s clinical development expertise, global delivery model and proprietary trial intelligence with Anthropic\u2019s frontier AI capabilities, we believe we can help sponsors make better decisions earlier, execute studies with greater precision and ultimately accelerate the delivery of medicines to patients.\u201d<\/p>\n

How Claude Will Be Deployed<\/p>\n

With support from Anthropic, ICON will develop four production capabilities within Orbis:<\/p>\n

Site intelligence and study planning: powering ICON\u2019s OneSearch and OnePlan tools with frontier model reasoning to sharpen site selection and study feasibility.<\/p>\n

Orbis predictive intelligence: enabling real-time detection of enrollment risks, trends and operational signals across active studies.<\/p>\n

Protocol optimization: applying AI to protocol design and scenario modelling to reduce amendments and accelerate study startup.<\/p>\n

Ecosystem integration: integrating ICON\u2019s clinical expertise into client systems, allowing them to securely access ICON\u2019s insights directly within Claude.<\/p>\n

ICON will deploy Claude across the organization through a targeted, role-based rollout: Claude Code for developers, Claude for knowledge teams, and Claude Science for scientific and clinical teams for maximum value creation.<\/p>\n

\u201cAI holds real potential to address long-standing challenges in clinical development and make a measurable difference for patients,\u201d said Pip White, Head of Ireland, UK and Northern Europe, Anthropic. \u201cFar too often, the barrier to getting medicines to patients faster is operational, not scientific. Take study enrollment as an example \u2013 it\u2019s one of the biggest bottlenecks in clinical development and causes delays in up to 80% of trials. This is exactly the kind of operational challenge that ICON\u2019s trial-delivery expertise, paired with Claude, is well suited to address.\u201d<\/p>\n

Earlier this year, BMS announced plans to deploy Claude<\/a> across its research, clinical development, manufacturing, commercial, and corporate functions.<\/p>\n","protected":false},"excerpt":{"rendered":"Editor\u2019s Take: From drug formulation to workflow automation, artificial intelligence (AI) is transforming life sciences. ICON is the…\n","protected":false},"author":2,"featured_media":789476,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[4,450,451,3,452,453],"class_list":["post-789475","post","type-post","status-publish","format-standard","has-post-thumbnail","category-breaking-news","tag-breaking-news","tag-breakingnews","tag-headlines","tag-news","tag-top-stories","tag-topstories"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts\/789475","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/comments?post=789475"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts\/789475\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/media\/789476"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/media?parent=789475"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/categories?post=789475"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/tags?post=789475"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}